Raziel Therapeutics

Company Overview

Snapshot

Founded in August 2012, Raziel Therapeutics operates with 1–10 employees. The company has raised $27.1M across 5 funding rounds from 9 investors.

Business overview

Raziel Therapeutics is a clinical-stage pharmaceutical company focused on developing proprietary injectable drugs for targeted fat reduction. The company's core technology involves a new chemical entity that converts white adipose tissue into brown adipose tissue, aiming to treat overweight and obese individuals. Its primary drug candidate, RZL-012, is designed to trigger fat-cell death and subsequent tissue shrinkage. Raziel Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, targeting chronic patients and individuals with conditions like obesity and diabetes.

Strategic signal

In July 2025, Raziel Therapeutics announced a strategic collaboration with 365mc, a leading South Korean medical institution specializing in fat reduction, to accelerate the development of RZL-012 in South Korea. This partnership signals a significant step in the company's global market expansion and validation of its drug candidate, indicating a strong potential for future commercialization and broader clinical adoption in the Asian market.

Company Intelligence Q&A

What is Raziel Therapeutics' primary drug candidate?

Raziel Therapeutics' primary drug candidate is RZL-012, an injectable drug currently in preclinical development designed for targeted fat reduction.

When was Raziel Therapeutics founded?

Raziel Therapeutics was founded in August 2012.

What was a significant strategic development for Raziel Therapeutics in July 2025?

In July 2025, Raziel Therapeutics announced a strategic collaboration with 365mc to accelerate the development of RZL-012 in South Korea, aiming to expand its market reach.

What was a key regulatory milestone for RZL-012?

In November 2019, Raziel Therapeutics received FDA approval to develop RZL-012 as an orphan drug for Dercum's disease.